Role of fibrinolysis in sepsis

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 4, 2013, Pages 392-399

  Gando, Satoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

disseminated intravascular coagulation (DIC); fibrinolysis; host defense; sepsis

Indexed keywords

LEUKOCYTE ELASTASE; OSTEOPONTIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOWN REGULATION; FIBRINOLYSIS; HOST RESISTANCE; HUMAN; INFLAMMATION; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE; MULTIPLE ORGAN FAILURE; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; PROTEIN DEGRADATION; REGULATORY MECHANISM; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION; THROMBOCYTE ACTIVATION; THROMBOSIS; TRANSCRIPTION INITIATION SITE; UPREGULATION;

ANIMALS; FIBRINOLYSIS; HUMANS; SEPSIS;

EID: 84878308850     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1334140     Document Type: Article

References (78)

1. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definition for sepsis and organ failure and guidelines for the use innovative therapies in sepsis. Crit Care Med: 1992; 20 6 864 874
2. Levi M., de Jonge E., van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis: 2003; 16 1-2 43 47 (Pubitemid 38477222)
3. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med: 2010; 38 (2, Suppl): S35 S42
4. Rangel-Frausto M. S., Pittet D., Costigan M., Hwang T., Davis C. S., Wenzel R. P. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA: 1995; 273 2 117 123
5. Maas C., Oschatz C., Renné T. The plasma contact system 2.0. Semin Thromb Hemost: 2011; 37 4 375 381
6. Nickel K. F., Renné T. Crosstalk of the plasma contact system with bacteria. Thromb Res: 2012; 130 01 S78 S83
7. Hack C. E. Fibrinolysis in disseminated intravascular coagulation. Semin Thromb Hemost: 2001; 27 6 633 638 (Pubitemid 33152575)
8. Plow E. F. The contribution of leukocyte proteases to fibrinolysis. Blut: 1986; 53 1 1 9
9. Plow E. F. Leucocyte elastase release during blood coagulation. J Clin Invest: 1982; 69 3 564 572
10. Kohno I., Inuzuka K., Itoh Y., et al. A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin: its application to the measurement of granulocyte-derived elastase digests in plasma. Blood: 2000; 95 5 1721 1728 (Pubitemid 30120835)
11. Bouma B. N., Meijers J. CM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost: 2003; 1 7 1566 1574
12. Degen J. L., Bugge T. H., Goguen J. D. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost: 2007; 5 01 24 31 (Pubitemid 46958813)
13. Bergmann S., Hammerschmidt S. Fibrinolysis and host response in bacterial infections. Thromb Haemost: 2007; 98 3 512 520 (Pubitemid 47412877)
14. Adib-Conquy M., Cavaillon J. M. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett: 2007; 581 19 3723 3733 (Pubitemid 47080996)
15. de Jong H. K., van der Poll T., Wiersinga W. J. The systemic pro-inflammatory response in sepsis. J Innate Immun: 2010; 2 5 422 430
16. Creagh E. M., O'Neill L. AJ. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol: 2006; 27 8 352 357 (Pubitemid 44038661)
17. Russell J. A., Boyd J., Nakada T., Thair S., Walley K. R. Molecular mechanisms of sepsis. Contrib Microbiol: 2011; 17 48 85
18. Esmon C. T. Inflammation and thrombosis. J Thromb Haemost: 2003; 1 7 1343 1348
19. Hoffman M., Monroe D. M. III. A cell-based model of hemostasis. Thromb Haemost: 2001; 85 6 958 965 (Pubitemid 32573743)
20. Semeraro N., Ammollo C. T., Semeraro F., Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res: 2012; 129 3 290 295
21. Suffredini A. F., Harpel P. C., Parrillo J. E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med: 1989; 320 18 1165 1172 (Pubitemid 19124297)
22. van Deventer S. JH, Büller H. R., ten Cate J. W., Aarden L. A., Hack C. E., Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood: 1990; 76 12 2520 2526
23. de Boer J. P., Creasy A. A., Chang A., et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock: 1993; 39 1 59 67 (Pubitemid 23019406)
24. Biemond B. J., Levi M., Ten Cate H., et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond): 1995; 88 5 587 594
25. Sawdey M. S., Podor T. J., Loskutoff D. J. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem: 1989; 264 18 10396 10401 (Pubitemid 19161600)
26. Sawdey M. S., Loskutoff D. J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest: 1991; 88 4 1346 1353
27. van der Poll T., Levi M., Büller H. R., et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med: 1991; 174 3 729 732
28. Jansen P. M., Boermeester M. A., Fischer E., et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood: 1995; 86 3 1027 1034
29. Stouthard J. ML, Levi M., Hack C. E., et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost: 1996; 76 5 738 742 (Pubitemid 26388179)
30. van der Poll T., de Jonge E., Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost: 2001; 27 6 639 651 (Pubitemid 33152576)
31. Pralong G., Calandra T., Glauser M. P., et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost: 1989; 61 3 459 462 (Pubitemid 19168155)
32. Páramo J. A., Pérez J. L., Serrano M., Rocha E. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost: 1990; 64 1 3 6 (Pubitemid 20301840)
33. Dofferhoff A. S., Bom V. JJ, de Vries-Hospers H. G., et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med: 1992; 20 2 185 192
34. Mesters R. M., Flörke N., Ostermann H., Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost: 1996; 75 6 902 907 (Pubitemid 26355345)
35. Robbie L. A., Dummer S., Booth N. A., Adey G. D., Bennett B. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. Br J Haematol: 2000; 109 2 342 348 (Pubitemid 30350715)
36. Madoiwa S., Nunomiya S., Ono T., et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol: 2006; 84 5 398 405 (Pubitemid 46052628)
37. Francis R. B. Jr, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations. J Lab Clin Med: 1987; 110 5 541 547 (Pubitemid 18033243)
38. Gando S., Kameue T., Nanzaki S., Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost: 1996; 75 2 224 228 (Pubitemid 26081471)
39. Hesselvik J. F., Blombäck M., Brodin B., Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med: 1989; 17 8 724 733 (Pubitemid 19199498)
40. Raaphorst J., Johan Groeneveld A. B., Bossink A. WJ, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost: 2001; 86 2 543 549 (Pubitemid 32743264)
41. Asakura H., Ontachi Y., Mizutani T., et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med: 2001; 29 6 1164 1168 (Pubitemid 32554329)
42. Kawamura T., Okada N., Okada H. Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol Immunol: 2002; 46 3 225 230 (Pubitemid 34289020)
43. Binette T. M., Taylor F. BJ Jr, Peer G., Bajzar L. Thrombin- thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood: 2007; 110 9 3168 3175 (Pubitemid 350106308)
44. Ravindranath T. M., Goto M., Iqbal O., et al. Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clin Appl Thromb Hemost: 2007; 13 4 362 368 (Pubitemid 350114524)
45. Wang Y. X., da Cunha V., Vincelette J., et al. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Part II. Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost: 2007; 97 1 54 61 (Pubitemid 46242387)
46. Muto Y., Suzuki K., Iida H., et al. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats. Crit Care Med: 2009; 37 5 1744 1749
47. Kim P. Y., Kim P. YG, Taylor F. BJ Jr, Nesheim M. E. Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis. J Thromb Thrombolysis: 2012; 33 4 412 415
48. Watanabe R., Wada H., Watanabe Y., et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res: 2001; 104 1 1 6 (Pubitemid 32918249)
49. Chen C. C., Lee K. D., Gau J. P., et al. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation. Ann Hematol: 2005; 84 10 675 680
50. Zeerleder S., Schroeder V., Hack C. E., Kohler H. P., Wuillemin W. A. TAFI and PAI-1 levels in human sepsis. Thromb Res: 2006; 118 2 205 212 (Pubitemid 43833324)
51. Emonts M., de Bruijne E. LE, Guimarães A. HC., et al. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost: 2008; 6 2 268 276 (Pubitemid 351144609)
52. Skeppholm M., Wallén N. H., Mobarrez F., Sollevi A., Soop A., Antovic J. P. Inflammation and thrombin generation causes increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia. Blood Coagl Fibrinol: 2009; 20 611 613
53. Hayakawa M., Sawamura A., Gando S., Jesmin S., Naito S., Ieko M. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. Thromb Res: 2012; 130 6 906 913
54. Sato T., Miwa T., Akatsu H., et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol: 2000; 165 2 1053 1058 (Pubitemid 30484776)
55. Morser J., Gabazza E. C., Myles T., Leung L. L. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost: 2010; 8 5 868 876
56. Renckens R., Roelofs J. JTH, ter Horst S. AJ., et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol: 2005; 175 10 6764 6771 (Pubitemid 41598921)
57. van Gorp E. CM, Minnema M. C., Suharti C., et al. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. Br J Haematol: 2001; 113 1 94 99 (Pubitemid 32423308)
58. Boffa M. B., Koschinsky M. L. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem: 2007; 40 7 431 442 (Pubitemid 46483325)
59. Ceresa E., Brouwers E., Peeters M., Jern C., Declerck P. J., Gils A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol: 2006; 26 2 423 428 (Pubitemid 43732210)
60. Rittirsch D., Flierl M. A., Ward P. A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol: 2008; 8 10 776 787
61. Markiewski M. M., Nilsson B., Ekdahl K. N., Mollnes T. E., Lambris J. D. Complement and coagulation: stranger or partners in the crime? Trends Immunol: 2010; 28 184 192 (Pubitemid 46476881)
62. Amara U., Flierl M. A., Rittirsch D., et al. Molecular intercommunication between the complement and coagulation systems. J Immunol: 2010; 185 9 5628 5636
63. Leung L. LK, Myles T., Nishimura T., Song J. J., Robinson W. H. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol: 2008; 45 16 4080 4083
64. Kamikura Y., Wada H., Nobori T., et al. Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with deep vein thrombosis. Thromb Res: 2005; 115 1-2 53 57 (Pubitemid 39572755)
65. Gando S., Kameue T., Sawamura A., Hayakawa M., Hoshino H., Kubota N. An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery. Thromb Res: 2007; 120 1 87 93 (Pubitemid 46601576)
66. Matsumoto T., Wada H., Nobori T., et al. Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost: 2005; 11 4 391 400 (Pubitemid 41546765)
67. Madoiwa S., Tanaka H., Nagahama Y., et al. Degradation of cross-linked fibrin by leukocyte elastase as alternative pathway for plasmin-mediated fibrinolysis in sepsis-induced disseminated intravascular coagulation. Thromb Res: 2011; 127 4 349 355
68. Gando S., Hayakawa M., Sawamura A., et al. The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation. Thromb Res: 2007; 121 1 67 73 (Pubitemid 350027772)
69. Johnson L. L., Berggren K. N., Szaba F. M., Chen W., Smiley S. T. Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med: 2003; 197 6 801 806 (Pubitemid 36350874)
70. Sodeinde O. A., Sample A. K., Brubaker R. R., Goguen J. D. Plasminogen activator/coagulase gene of Yersinia pestis is responsible for degradation of plasmid-encoded outer membrane proteins. Infect Immun: 1988; 56 10 2749 2752
71. Frick I. M., Björck L., Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost: 2007; 98 3 497 502 (Pubitemid 47412875)
72. Frick I. M., Åkesson P., Herwald H., et al. The contact system-a novel branch of innate immunity generating antibacterial peptides. EMBO J: 2006; 25 23 5569 5578 (Pubitemid 44847197)
73. Renckens R., Pater J. M., van der Poll T. Plasminogen activator inhibitor type-1-deficient mice have an enhanced IFN-gamma response to lipopolysaccharide and staphylococcal enterotoxin B. J Immunol: 2006; 177 11 8171 8176 (Pubitemid 44846337)
74. Renckens R., Roelofs J. JTH, Bonta P. I., et al. Plasminogen activator inhibitor type 1 is protective during severe gram-negative pneumonia. Blood: 2007; 109 4 1593 1601 (Pubitemid 46239593)
75. Kager L. M., Wiersinga W. J., Roelofs J. J., et al. Plasminogen activator inhibitor type I contributes to protective immunity during experimental gram-negative sepsis (melioidosis). J Thromb Haemost: 2011; 9 10 2020 2028
76. Luo D., Szaba F. M., Kummer L. W., et al. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica. J Immunol: 2011; 187 4 1866 1876
77. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med: 2012; 40 9 2704 2708
78. Taylor F. BJ Jr, Toh C. H., Hoots W. K., Wada H., Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost: 2001; 86 5 1327 1330